• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort.在一个大型高血压队列中,血浆肾素活性及其与缺血性心脏病、充血性心力衰竭和脑血管病的关系。
J Clin Hypertens (Greenwich). 2014 Nov;16(11):805-13. doi: 10.1111/jch.12419. Epub 2014 Sep 25.
2
Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort.血浆肾素活性和醛固酮-肾素比值与慢性肾脏病患病率的关系:凯撒永久南加州队列研究。
J Hypertens. 2011 Nov;29(11):2226-35. doi: 10.1097/HJH.0b013e32834bbc8a.
3
Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).血浆肾素活性是否可作为预测降压治疗的高血压患者肾脏和心血管结局的生物标志物?来自盎格鲁-斯堪的纳维亚心脏结局试验(ASCOT)的观察。
Eur Heart J. 2012 Dec;33(23):2970-9. doi: 10.1093/eurheartj/ehs241. Epub 2012 Aug 31.
4
Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.血浆肾素活性(PRA)水平与大型医疗保健系统中的降压药物使用情况。
Am J Hypertens. 2012 Mar;25(3):379-88. doi: 10.1038/ajh.2011.216. Epub 2011 Dec 8.
5
Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease.基线时血浆肾素活性升高与经血管造影证实的冠心病患者心脏事件的关系。
Am J Cardiol. 2010 Sep 15;106(6):764-9. doi: 10.1016/j.amjcard.2010.04.040. Epub 2010 Aug 1.
6
Distinct determinants of muscle wasting in nonobese heart failure patients with and without type 2 diabetes mellitus.非肥胖心力衰竭伴和不伴 2 型糖尿病患者肌肉减少症的不同决定因素。
J Diabetes. 2021 Jan;13(1):7-18. doi: 10.1111/1753-0407.13090. Epub 2020 Sep 2.
7
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).PEAR 研究(抗高血压反应的药物基因组学评估)中影响高血压患者血浆肾素活性的遗传变异。
Circ Genom Precis Med. 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854.
8
Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.在血压得到控制、未得到控制的难治性和非难治性高血压患者中,肾脏、心血管及死亡结局的比较风险
Kidney Int. 2015 Sep;88(3):622-32. doi: 10.1038/ki.2015.142. Epub 2015 May 6.
9
Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.伴有和不伴有氮血症的高血压猫的血浆肾素活性和醛固酮浓度以及对苯磺酸氨氯地平治疗的反应。
J Vet Intern Med. 2014 Jan-Feb;28(1):144-53. doi: 10.1111/jvim.12240. Epub 2013 Nov 13.
10
Normokalemic hyperaldosteronism in patients with resistant hypertension.顽固性高血压患者的正常血钾性醛固酮增多症
Isr Med Assoc J. 2002 Jan;4(1):17-20.

引用本文的文献

1
Renin: Measurements, Correlates, and Associations With Long-Term Adverse Kidney Outcomes.肾素:测量、相关因素和与长期不良肾脏结局的关联。
Am J Hypertens. 2023 Jan 1;36(1):42-49. doi: 10.1093/ajh/hpac112.
2
Renin Activity in Heart Failure with Reduced Systolic Function-New Insights.心力衰竭伴收缩功能障碍患者肾素活性的新认识。
Int J Mol Sci. 2019 Jun 28;20(13):3182. doi: 10.3390/ijms20133182.
3
Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure.血压升高和未升高个体的血浆肾素活性与心血管及死亡结局风险
Kidney Res Clin Pract. 2016 Dec;35(4):219-228. doi: 10.1016/j.krcp.2016.07.004. Epub 2016 Jul 26.

本文引用的文献

1
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.一个综合性医疗体系中,大型、种族多样化的高血压人群中耐药性高血压的特征。
Mayo Clin Proc. 2013 Oct;88(10):1099-107. doi: 10.1016/j.mayocp.2013.06.017.
2
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels.肾素-血管紧张素系统阻滞剂可能会给低钠血症且血浆肾素水平高的心血管病患者带来更多风险而非获益。
Am J Hypertens. 2013 Jun;26(6):727-38. doi: 10.1093/ajh/hpt034. Epub 2013 Apr 2.
3
Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.一个大型综合医疗保健系统成员的社会人口学特征:与美国人口普查局数据的比较。
Perm J. 2012 Summer;16(3):37-41. doi: 10.7812/TPP/12-031.
4
Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).血浆肾素活性是否可作为预测降压治疗的高血压患者肾脏和心血管结局的生物标志物?来自盎格鲁-斯堪的纳维亚心脏结局试验(ASCOT)的观察。
Eur Heart J. 2012 Dec;33(23):2970-9. doi: 10.1093/eurheartj/ehs241. Epub 2012 Aug 31.
5
Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.血浆肾素活性(PRA)水平与大型医疗保健系统中的降压药物使用情况。
Am J Hypertens. 2012 Mar;25(3):379-88. doi: 10.1038/ajh.2011.216. Epub 2011 Dec 8.
6
Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort.血浆肾素活性和醛固酮-肾素比值与慢性肾脏病患病率的关系:凯撒永久南加州队列研究。
J Hypertens. 2011 Nov;29(11):2226-35. doi: 10.1097/HJH.0b013e32834bbc8a.
7
Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients.在高血压患者中,基线血浆肾素活性与全因和心血管死亡率存在持久的直接关联。
Am J Hypertens. 2011 Nov;24(11):1181-6. doi: 10.1038/ajh.2011.172. Epub 2011 Sep 22.
8
Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 intake, inflammation, and survival in long-term hemodialysis patients.长期血液透析患者的饮食 ω-3 脂肪酸、ω-6 与 ω-3 摄入比例、炎症与生存。
Am J Kidney Dis. 2011 Aug;58(2):248-56. doi: 10.1053/j.ajkd.2011.03.017. Epub 2011 Jun 12.
9
Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study.血浆肾素活性可预测心脏结局预防评估(HOPE)研究中的心血管死亡率。
Eur Heart J. 2011 Sep;32(17):2135-42. doi: 10.1093/eurheartj/ehr066. Epub 2011 Mar 17.
10
25-hydroxyvitamin D levels and hypertension rates.25-羟维生素 D 水平与高血压发病率。
J Clin Hypertens (Greenwich). 2011 Mar;13(3):170-7. doi: 10.1111/j.1751-7176.2010.00408.x. Epub 2010 Dec 22.

在一个大型高血压队列中,血浆肾素活性及其与缺血性心脏病、充血性心力衰竭和脑血管病的关系。

Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort.

机构信息

Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.

出版信息

J Clin Hypertens (Greenwich). 2014 Nov;16(11):805-13. doi: 10.1111/jch.12419. Epub 2014 Sep 25.

DOI:10.1111/jch.12419
PMID:25255792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4224980/
Abstract

Plasma renin activity (PRA) may be a surrogate for vascular damage. The authors hypothesize that PRA is associated with cardiovascular and cerebrovascular disease (CED). A cross-sectional study (January 1, 1998, to December 31, 2009) was performed on hypertensive individuals 18 years and older using multivariable logistic regression models to estimate odds ratios (ORs) for ischemic heart disease (IHD), congestive heart failure (CHF), and CED based on PRA quartiles controlling for age, sex, race, diabetes mellitus (DM), and medication use. Among 7887 individuals (60% women; 34% whites, 23% blacks, and 19% Hispanics; and 29% with DM), the adjusted ORs (95% CI) for IHD were 0.94 (0.80-1.10), 1.09 (0.92-1.29), and 1.18 (1.00-1.39); for CHF were 1.23 (0.99-1.53), 1.27 (1.01-1.61), and 1.41 (1.13-1.77); and for CED were 0.95 (0.78-1.17), 0.77 (0.61-0.97), and 0.97 (0.78-1.20) for the second, third, and fourth quartiles compared with the first quartile. Higher PRA was associated with greater likelihood for prevalent IHD and CHF but not CED in this large ethnically diverse population of hypertensive individuals.

摘要

血浆肾素活性(PRA)可能是血管损伤的替代指标。作者假设 PRA 与心血管和脑血管疾病(CED)有关。本研究采用多变量逻辑回归模型,对 1998 年 1 月 1 日至 2009 年 12 月 31 日期间年龄在 18 岁及以上的高血压患者进行了一项横断面研究,以估计基于 PRA 四分位数的缺血性心脏病(IHD)、充血性心力衰竭(CHF)和 CED 的比值比(OR),同时控制年龄、性别、种族、糖尿病(DM)和药物使用情况。在 7887 名患者(60%为女性;34%为白人,23%为黑人,19%为西班牙裔;29%患有 DM)中,IHD 的校正 OR(95%CI)为 0.94(0.80-1.10)、1.09(0.92-1.29)和 1.18(1.00-1.39);CHF 的校正 OR(95%CI)为 1.23(0.99-1.53)、1.27(1.01-1.61)和 1.41(1.13-1.77);CED 的校正 OR(95%CI)为 0.95(0.78-1.17)、0.77(0.61-0.97)和 0.97(0.78-1.20),第二、三、四分位数与第一四分位数相比。在这个由不同种族组成的大型高血压患者群体中,较高的 PRA 与较高的 IHD 和 CHF 发生率相关,但与 CED 无关。